The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••

E•••••• C••••••• R••••••• Expands Global Biometrics Capabilities with Acquisition of F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••

Add-on acquisitionannouncedadd-onannounced Sep 17, 2026Fact
What happened
Target
F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••
Platform
E•••••• C••••••• R•••••••add-on basis: E•••••• is a portfolio company of A•••••••• C•••••• P••••••• (“A••••••••”), a Washington, D.C.-area private equity firm with extensive experience investing in regulated industries.
Control
Control
Share acquired
unknown
Industry
healthcare / clinic
Target location
unknown
Seller kind
Corporate parent
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
7 named
Buy side
  • M•••••• L•••••Deal partnerconfirmed
    ““As clinical development grows more global and complex, sponsors need partners with the scale, expertise, and integrated capabilities to support programs across geographies and regulatory environments,” said M•••••• L•••••, a partner at A•••••••• C•••••• P•••••••.”
  • E•••••• C••••••• R•••••••Platformconfirmed
    “E•••••• is a portfolio company of A•••••••• C•••••• P••••••• (“A••••••••”), a Washington, D.C.-area private equity firm with extensive experience investing in regulated industries.”
  • A•••••••• C•••••• P•••••••Sponsorconfirmed
    “E•••••• is a portfolio company of A•••••••• C•••••• P••••••• (“A••••••••”), a Washington, D.C.-area private equity firm with extensive experience investing in regulated industries.”
Sell side
  • F•••• C••••••• R•••••••Sellerconfirmed
    “E•••••• C••••••• R••••••• Expands Global Biometrics Capabilities with Acquisition of F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••”
Side not stated
  • J•• D••Managementconfirmed
    ““This acquisition reflects our continued investment in exceptional clinical data science talent and reinforces our commitment to helping clients bring therapies to patients faster,” said J•• D••, Chief Executive Officer of E••••••.”
  • R•• W••••••Managementconfirmed
    ““We are delighted to welcome these talented professionals to E••••••,” said R•• W••••••, Chief Operating Officer of E••••••.”
  • F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••Targetconfirmed
    “E•••••• C••••••• R••••••• Expands Global Biometrics Capabilities with Acquisition of F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••”
Evidence
“E•••••• C••••••• R••••••• Expands Global Biometrics Capabilities with Acquisition of F•••• C••••••• R••••••••• D••• S••••••• B••••••• U•••”
Press release wires (PR Newswire, GlobeNewswire, B••••••• Wire public pages and RSS)confidence 80%recorded Sep 21, 2026
E•••••• C••••••• R••••••• Expands Global Biometrics Capabilities with Acquisition of F•••• | Private Equity Intelligence | DFX